Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).
about
Is levorphanol a better option than methadone?A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceDifferences in Methadone Metabolism by CYP2B6 VariantsCyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics.Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and MetabolismMethadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.Role of cytochrome P4502B6 in methadone metabolism and clearance.Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenanceMechanism of autoinduction of methadone N-demethylation in human hepatocytes.Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease.Ritonavir Use in Human Immunodeficiency Virus-Positive Surgical Patients Is Not Associated with an Increase in Postoperative Critical Respiratory Events.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.Current Concepts in Methadone Metabolism and Transport.Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.Drug interactions with methadone: Time to revise the product label.
P2860
Q26797376-05ECEA24-AEF4-4C5B-8DBC-0495B4B57732Q27692040-1A1C584A-0D12-400B-A84B-802F63150905Q35745266-3983E439-546E-4E54-832F-AC9AEC580E62Q36036200-310E3A02-1580-4BB1-AA6D-0570380CBDF3Q36342286-F63251EB-A187-49F3-A951-0D3219806DF1Q36717150-07FA9358-F8F2-4E91-BFC2-8FE8878138FCQ37094439-75F2C276-0E50-4A77-B682-79F680D8A1A7Q37325606-D050E1EF-DBDC-46B8-AA8E-ABB3AB4BD7C3Q37335799-9902AEE7-9157-4EB6-BFB7-92A1D2A01CFDQ37409042-7A085B8A-AFED-4714-8151-30A424A9298CQ37631831-285D5966-3554-435C-BC1D-E1D3A4A40E6BQ38478413-C1F9018A-DE81-40F8-95D4-2B404BF935F8Q39165843-DCB20252-6DC3-430A-A8EA-FAC59AA2497DQ40797971-2E38613F-C9DE-4C9C-9724-C4D9476C680CQ50668713-12C028D5-E701-48BA-A1B9-8AEC71169161Q50682107-BE679D9E-E5FA-4A4B-B1A8-28F50D33E99DQ50924422-A00ADCB7-6F89-419C-8A8D-42952B42B211Q53544619-F01D9835-485F-4A45-9C98-400F31532227Q54646435-B1626C40-33C6-4109-A255-A8501DDA86D6
P2860
Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Lack of indinavir effects on m ...... nal cytochrome P4503A (CYP3A).
@ast
Lack of indinavir effects on m ...... nal cytochrome P4503A (CYP3A).
@en
type
label
Lack of indinavir effects on m ...... nal cytochrome P4503A (CYP3A).
@ast
Lack of indinavir effects on m ...... nal cytochrome P4503A (CYP3A).
@en
prefLabel
Lack of indinavir effects on m ...... nal cytochrome P4503A (CYP3A).
@ast
Lack of indinavir effects on m ...... nal cytochrome P4503A (CYP3A).
@en
P2093
P2860
P1433
P1476
Lack of indinavir effects on m ...... nal cytochrome P4503A (CYP3A).
@en
P2093
Alysa Walker
Christine Hoffer
Dale Whittington
Evan D Kharasch
Pamela Sheffels Bedynek
P2860
P304
P356
10.1097/ALN.0B013E3182423478
P407
P577
2012-02-01T00:00:00Z